Literature DB >> 15197335

Opioid peptides in cancer.

Jakub Fichna1, Anna Janecka.   

Abstract

Opioid and somatostatin systems are two main inhibitory systems in mammals implicated in a variety of processes from hormone secretion to the modulation of cell proliferation. Opioids and opioid receptors were found in a great diversity of primary human tumors and in various cancer cell lines. A new area of interest that has developed since the early 1980s has been concerned with the role of endogenous opioid systems in the growth of normal and abnormal tissues and cells. This review presents recent developments on the identification of opioid ligands and receptors in different types of human neoplasia. It also deals with the mechanisms of opioid peptide action in carcinoma and the involvement of opioids in the regulation of tumor growth.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15197335     DOI: 10.1023/B:CANC.0000031773.46458.63

Source DB:  PubMed          Journal:  Cancer Metastasis Rev        ISSN: 0167-7659            Impact factor:   9.264


  16 in total

1.  Delta-Opioid Receptor (δOR) Targeted Near-Infrared Fluorescent Agent for Imaging of Lung Cancer: Synthesis and Evaluation In Vitro and In Vivo.

Authors:  Allison S Cohen; Renata Patek; Steven A Enkemann; Joseph O Johnson; Tingan Chen; Eric Toloza; Josef Vagner; David L Morse
Journal:  Bioconjug Chem       Date:  2015-10-30       Impact factor: 4.774

2.  Design, synthesis and evaluation of 111In labeled DOTA-conjugated tetrapeptides having high affinity and selectivity for mu opioid receptors.

Authors:  John R Lever; Emily A Fergason-Cantrell; Terry L Carmack; Lisa D Watkinson; Fabio Gallazzi
Journal:  Nucl Med Biol       Date:  2019-03-07       Impact factor: 2.408

3.  Chitosan nanoparticles are efficient carriers for delivering biodegradable drugs to neuronal cells.

Authors:  M Malatesta; V Galimberti; B Cisterna; M Costanzo; M Biggiogera; C Zancanaro
Journal:  Histochem Cell Biol       Date:  2013-12-20       Impact factor: 4.304

4.  Macrocyclic peptides decrease c-Myc protein levels and reduce prostate cancer cell growth.

Authors:  Archana Mukhopadhyay; Laura E Hanold; Hamsa Thayele Purayil; Solomon A Gisemba; Sanjeewa N Senadheera; Jane V Aldrich
Journal:  Cancer Biol Ther       Date:  2017-07-10       Impact factor: 4.742

5.  Tumor Targeting and Pharmacokinetics of a Near-Infrared Fluorescent-Labeled δ-Opioid Receptor Antagonist Agent, Dmt-Tic-Cy5.

Authors:  Amanda Shanks Huynh; Veronica Estrella; Valerie E Stark; Allison S Cohen; Tingan Chen; Todd J Casagni; Jatinder S Josan; Mark C Lloyd; Joseph Johnson; Jongphil Kim; Victor J Hruby; Josef Vagner; David L Morse
Journal:  Mol Pharm       Date:  2016-01-08       Impact factor: 4.939

6.  MOR1 expression in gastric cancer: a biomarker associated with poor outcome.

Authors:  Ya-sai Yao; Ru-yong Yao; Li-kun Zhuang; Wei-wei Qi; Jing Lv; Fei Zhou; Wen-sheng Qiu; Lu Yue
Journal:  Clin Transl Sci       Date:  2014-12-02       Impact factor: 4.689

7.  Solid-phase synthetic strategy and bioevaluation of a labeled delta-opioid receptor ligand Dmt-Tic-Lys for in vivo imaging.

Authors:  Jatinder S Josan; David L Morse; Liping Xu; Maria Trissal; Brenda Baggett; Peg Davis; Josef Vagner; Robert J Gillies; Victor J Hruby
Journal:  Org Lett       Date:  2009-06-18       Impact factor: 6.005

Review 8.  The role of morphine in regulation of cancer cell growth.

Authors:  Katarzyna Gach; Anna Wyrębska; Jakub Fichna; Anna Janecka
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-07-29       Impact factor: 3.000

9.  Effects of sufentanil on human gastric cancer cell line SGC-7901 in vitro.

Authors:  Weidong Wu; Ningxian Wei; Chun-Nan Jiang; Suyang Cui; Jintao Yuan
Journal:  Cent Eur J Immunol       Date:  2014-10-14       Impact factor: 2.085

Review 10.  Opioids, Neutral Endopeptidase, its Inhibitors and Cancer: Is There a Relationship among them?

Authors:  Magdalena Mizerska-Dudka; Martyna Kandefer-Szerszeń
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2014-09-06       Impact factor: 4.291

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.